$PYPD News

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...

PolyPid Ltd. Q2 2026 Earnings Call Summary

PolyPid Q2 Earnings Call Highlights

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28

Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid

HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site Infections

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

PolyPid (PYPD) Q1 2026 Earnings Transcript

PolyPid Q1 Earnings Call Highlights